NCT04746209 - Blinatumomab After TCR Alpha Beta/CD19 Depleted HCT | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

February 1, 2021

Primary Completion Date

February 28, 2024

Study Completion Date

December 31, 2029

Conditions

B-cell Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaB-Cell ALL, Childhood

Interventions

DEVICE

Alpha/Beta T-cell and B-cell depleted HCT

Device: Alpha/Beta T-cell and B-cell depletion

DRUG

Blinatumomab

28 day continuous infusion given on Day 100 post-HCT if no significant ongoing GVHD

Trial Locations (1)

RECRUITING

Children's Hospital of Wisconsin, Milwaukee